Aldea Pharmaceuticals is focused on developing small molecule modulators of the aldehyde dehydrogenase enzyme superfamily. The scientific approach was discovered by Stanford University researchers and exclusively licensed to Aldea. Aldea is pursuing treatment of clinically significant acute alcohol toxicity, Fanconi anemia and other diseases and conditions associated with toxic aldehydes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/25/14 | $24,000,000 | Series B |
Canaan Partners Correlation Ventures RusnanoMedInvest WuXi PharmaTech | undisclosed |
